On a spring morning in Groningen, researchers at the University Medical Center Groningen (UMCG) began recruiting Parkinson’s disease patients for a pivotal clinical trial. The study marks the first time a locally developed medication, SUL-238, will be tested for effectiveness in people living with the neurodegenerative condition. This milestone represents years of collaborative work between Groningen-based scientists, biotech firms, and academic institutions aiming to address a fundamental aspect of Parkinson’s pathology: disrupted cellular energy production.
The investigational pill, SUL-238, originated from research inspired by hibernation biology. Scientists observed that certain animals can drastically reduce their metabolic rate during winter months without suffering cellular damage, suggesting that enhancing cellular energy management could be a viable therapeutic strategy. This concept led to the development of SUL-238, which targets mitochondria — the structures within cells responsible for generating energy. Preclinical studies indicated the compound was well-tolerated in healthy volunteers, with no significant adverse effects reported, paving the way for human trials in patient populations.
According to verified reports, the UMCG launched patient recruitment for a Phase 2A study in March 2026. The trial is designed to assess the safety, tolerability, and early signals of efficacy of SUL-238 in individuals diagnosed with Parkinson’s disease. Neurologist Professor Teus van Laar of the UMCG is leading the investigation, which is financially supported by the Turkish pharmaceutical company GEN Ilac, following their acquisition of rights to the compound. The study focuses on determining whether the drug can positively influence the energy homeostasis of neurons affected by Parkinson’s, potentially slowing symptom progression.
The development of SUL-238 has been a long-standing regional effort. Work began in 2012 at Sulfateq, a Groningen-based biotechnology company, in collaboration with partners including Syncom, ABL, the UMCG, and the Hanze University of Applied Sciences. The active pharmaceutical ingredient is manufactured by Ofichem in Ter Apel, a municipality in the northeastern Netherlands. Over the years, the project has contributed to thirteen doctoral theses, reflecting its deep integration into the local academic and scientific ecosystem. Key contributors include Dr. Guido Krenning, whose research on mitochondrial function has been central to understanding how SUL-238 may support cellular energy production, and Dr. Nadir Ulu, whose work on organ damage has informed preclinical and clinical development.
If the Phase 2A trial yields positive results, researchers plan to explore whether SUL-238 could have broader applications beyond Parkinson’s disease. The medication’s mechanism — targeting mitochondrial efficiency — raises potential relevance for other conditions characterized by impaired cellular energy metabolism. These include Alzheimer’s disease, heart failure, chronic kidney disease, chronic obstructive pulmonary disease (COPD), and sepsis. Scientists caution, however, that such expansions would require additional rigorous testing and are contingent upon successful outcomes in the current Parkinson’s-focused study.
Understanding the Science Behind SUL-238
Mitochondrial dysfunction has increasingly been recognized as a contributing factor in Parkinson’s disease. Neurons in the substantia nigra, a brain region critical for movement control, are particularly vulnerable to energy deficits due to their high metabolic demands. When mitochondria fail to produce adequate adenosine triphosphate (ATP), the primary energy currency of cells, neurons may undergo oxidative stress and eventual degeneration. This process is believed to play a role in the loss of dopamine-producing cells that underlies motor symptoms such as tremor, rigidity, and bradykinesia.
SUL-238 is designed to modulate mitochondrial activity, aiming to restore or enhance energy production in stressed cells. By improving the efficiency of the electron transport chain — a series of protein complexes within the mitochondrial inner membrane — the compound may assist neurons maintain function under conditions of metabolic strain. Preclinical models have shown that SUL-238 can support ATP synthesis and reduce markers of cellular stress, although translation to human efficacy remains to be demonstrated in ongoing trials.
The approach represents a shift from symptomatic treatment toward disease modification. Current Parkinson’s therapies primarily focus on replenishing dopamine or mimicking its effects, which can alleviate motor symptoms but do not halt the underlying neurodegenerative process. Interventions targeting mitochondrial health, like SUL-238, aim to address a root cause of neuronal decline, potentially offering neuroprotective benefits. However, experts emphasize that proving disease modification in human trials requires long-term data showing slowed clinical progression, a benchmark not yet met by any approved Parkinson’s therapy.
Regional Collaboration and Development Timeline
The journey of SUL-238 from concept to clinical trial exemplifies the power of localized scientific ecosystems. Initial conceptualization is credited to Rob Henning, a researcher whose interest in hibernation physiology sparked the idea that enhancing cellular resilience could yield therapeutic applications. Henning collaborated with Sulfateq to advance the compound through early development stages, leveraging the company’s expertise in drug discovery and formulation.
Key milestones in the development process include:
- 2012: Initiation of SUL-238 development by Sulfateq in partnership with regional institutions.
- Preclinical testing: Demonstration of safety and tolerability in healthy human volunteers.
- March 2026: UMCG begins patient recruitment for Phase 2A trial in Parkinson’s disease.
- Ongoing: Investigation led by Prof. Teus van Laar, funded by GEN Ilac following rights acquisition.
The production of SUL-238’s active ingredient occurs entirely within the Netherlands, with Ofichem in Ter Apel handling synthesis. This localized supply chain underscores the project’s commitment to regional development and quality control. Collaborative contributions from the Hanze University of Applied Sciences have included analytical support and process optimization, although ABL and Syncom have provided specialized chemical manufacturing and formulation expertise.
Academic leadership has been instrumental in translating laboratory findings into clinical investigation. Prof. Teus van Laar brings extensive experience in movement disorders and clinical trial design to the study, having previously led investigations into novel Parkinson’s therapies. His team at the UMCG’s Department of Neurology is responsible for patient screening, treatment administration, and monitoring of clinical and biomarker outcomes throughout the trial period.
What This Means for Patients and Future Research
For individuals living with Parkinson’s disease, the initiation of this trial offers access to an investigational approach that differs from existing treatments. While participation in clinical research involves uncertainties — including the possibility of receiving a placebo or experiencing unknown side effects — it as well provides an opportunity to contribute to scientific understanding of potential disease-modifying strategies. Eligibility criteria for the study likely include confirmed Parkinson’s diagnosis, specific disease stage parameters, and absence of certain comorbidities, though exact enrollment details have not been publicly disclosed in verified sources.
The broader implications extend beyond individual patient outcomes. A successful demonstration of SUL-238’s efficacy could validate mitochondrial-targeted therapy as a viable avenue for neurodegenerative disease intervention. This would encourage further investment in similar approaches and potentially accelerate timelines for testing in related conditions. Conversely, if the trial fails to show meaningful benefit, it would still provide valuable data on the limitations of energy-focused interventions in complex neurological disorders.
Researchers have noted that even if SUL-238 proves effective for Parkinson’s, regulatory approval would require additional phases of testing. A Phase 2A study, while critical for establishing preliminary efficacy and safety, is insufficient for market authorization. Subsequent steps would involve larger Phase 2B or Phase 3 trials to confirm effectiveness, monitor adverse reactions, and compare the drug against existing therapies or placebo in more diverse populations.
As of now, no official completion date for the current study has been published in verified sources. The next expected milestone is the release of top-line results from the Phase 2A trial, which will determine whether the investigation advances to later stages or is reconsidered based on outcome data. Individuals seeking updates are advised to consult clinical trial registries such as ClinicalTrials.gov or the EU Clinical Trials Register, where study identifiers and status changes are typically posted.
The development of SUL-238 highlights how localized scientific innovation, when supported by cross-sector collaboration, can contribute to global medical progress. From a hypothesis rooted in animal hibernation to a pill undergoing human testing in the northern Netherlands, the journey reflects the iterative nature of translational research — where basic biological insights are gradually shaped into potential therapies through rigorous, step-by-step investigation.
For readers interested in following this story, verified updates will be available through official channels including the UMCG’s press office, peer-reviewed scientific publications upon study completion, and regulatory announcements if and when the drug advances toward approval. Engaging with these sources ensures access to accurate, timely information as the scientific process unfolds.
We invite you to share your thoughts on this development in the comments below. Have you or someone you know participated in a clinical trial for Parkinson’s disease? What hopes or concerns do you have about emerging treatments targeting cellular mechanisms? Your perspectives help foster informed discussion about the future of neurological health research.